|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:abbreviation
|
gptkb:PPI
|
|
gptkbp:ATCCode
|
gptkb:A02BC
|
|
gptkbp:category
|
gptkb:pharmacy
Gastroenterology
Acid suppressants
|
|
gptkbp:contraindication
|
Known hypersensitivity
|
|
gptkbp:contrastsWith
|
H2 receptor antagonist
|
|
gptkbp:developedBy
|
Astra AB (Omeprazole)
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:drugInteraction
|
gptkb:Warfarin
gptkb:Methotrexate
gptkb:Clopidogrel
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:example
|
gptkb:Esomeprazole
gptkb:Lansoprazole
gptkb:Omeprazole
gptkb:Pantoprazole
Rabeprazole
|
|
gptkbp:form
|
gptkb:tablet
gptkb:Injection
Capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Proton Pump Inhibitor
|
|
gptkbp:legalStatus
|
Prescription only
Over-the-counter (some countries)
|
|
gptkbp:mechanismOfAction
|
Inhibits H+/K+ ATPase enzyme
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:notableFor
|
Most potent acid suppressors
|
|
gptkbp:pregnancyCategory
|
Varies by drug
|
|
gptkbp:reduces
|
Gastric acid secretion
|
|
gptkbp:riskFactor
|
Increased risk of gastrointestinal infections
Increased risk of kidney disease
Increased risk of pneumonia
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
Intravenous
|
|
gptkbp:sideEffect
|
gptkb:Vitamin_B12_deficiency
gptkb:Nausea
gptkb:Clostridioides_difficile_infection
Headache
Osteoporosis
Diarrhea
Abdominal pain
Hypomagnesemia
|
|
gptkbp:usedFor
|
gptkb:Zollinger-Ellison_syndrome
Gastroesophageal reflux disease
Peptic ulcer disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
Yes
|
|
gptkbp:bfsParent
|
gptkb:PPN
gptkb:PPI
|
|
gptkbp:bfsLayer
|
7
|